C4 Therapeutics Inc (CCCC)vsRoyalty Pharma Plc (RPRX)
CCCC
C4 Therapeutics Inc
$3.85
-7.67%
HEALTHCARE · Cap: $393.62M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 6689% more annual revenue ($2.44B vs $35.95M). RPRX leads profitability with a 33.9% profit margin vs -292.1%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
CCCC
Avoid34
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.3%
Fair Value
$4.99
Current Price
$3.85
$1.14 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 112.8% year-over-year
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -44.3% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CCCC
The strongest argument for CCCC centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 112.8% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : CCCC
The primary concerns for CCCC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
CCCC profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
CCCC carries more volatility with a beta of 2.78 — expect wider price swings.
CCCC is growing revenue faster at 112.8% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 34/100), backed by strong 33.9% margins and 11.0% revenue growth. CCCC offers better value entry with a 63.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
C4 Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?